English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduEvery day, scientists across Cedars-Sinai’s vast research and clinical enterprise are focused on developing medical discoveries and breakthroughs to improve health outcomes.
Tag: Cell Therapy
A gene mutation associated with a rare neurological disorder and increased susceptibility to viral infections may be treatable with oleic acid
A mutation in a protein regulating natural killer (NK) cells’ function is at the root of immune deficiency in some people with a rare genetic condition characterized by cognitive and developmental delay, seizures, and other manifestations. The findings also have broader implications for immunity and cell therapies.
Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects
Pulmonary diseases across all ages threaten millions of people and have emerged as one of the major public health issues worldwide. For diverse disease conditions, the currently available approaches are focused on alleviating clinical sympt
Cellular preconditioning and mesenchymal stem cell ferroptosis
In this editorial, we comment on the article published in the recent issue of the World Journal of Stem Cells. They focus on stem cell preconditioning to prevent ferroptosis by modulating the cystathionine γ-lyase/hydrogen sulfide (H2S) pa
MD Anderson acquires inducible switch technologies for cell therapy
MD Anderson has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDE switch and GoCAR platforms. As a result, MD Anderson may incorporate these technologies into its own cell therapy programs as well as make them available for licensing to interested parties.
NUS scientists develop innovative magnetic gel that heals diabetic wounds three times faster
A team of researchers from the National University of Singapore has engineered an innovative magnetic wound-healing gel that promises to heal diabetic wounds three times faster, reduce the rates of recurrence, and in turn, lower the incidents of limb amputations.
The innovative magnetic hydrogel, which contains skin cells for healing as well as magnetic particles, takes a comprehensive ‘all-in-one’ approach to wound healing, accelerating the process on several fronts. To maximise therapeutic results, a wireless external magnetic device is used to activate skin cells and accelerate the wound healing process. A patent has been filed for this innovation.
Interferon-γ priming enhances the therapeutic effects of menstrual blood-derived stromal cells in a mouse liver ischemia-reperfusion model
BACKGROUNDMesenchymal stem cells (MSCs) have been used in liver transplantation and have certain effects in alleviating liver ischemia-reperfusion injury (IRI) and regulating immune rejection. However, some studies have indicated that the e
Cell therapy can reduce risk of death from COVID-19 by 60%, study shows
The use of cell therapy to treat COVID-19 patients can reduce the risk of death from the disease by 60%, according to a systematic review and meta-analysis conducted by researchers at the University of São Paulo (USP) in Brazil, in partnership with colleagues in Germany and the United States.
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for sarcoma
MD Anderson and Replay announced that the FDA has issued a ‘safe to proceed’ for the Investigational New Drug application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for sarcoma.
CHOP Researchers Identify Molecules that Optimize Immune Presentation of Antigens across the Human Population
Researchers at Children’s Hospital of Philadelphia (CHOP) have identified variants of a chaperone molecule that optimizes the binding and presentation of foreign antigens across the human population, which could open the door to numerous applications where robust presentation to the immune system is important, including cell therapy and immunization. The findings were published today in Science Advances.
MD Anderson and KKR-backed Replay form new product company Syena to pioneer first-in-class TCR NK cell therapy
MD Anderson and Replay announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR) natural killer (NK) cell therapies.
CHOP Researchers Develop Tool that Reduces Errors in Stem Cell Transplant Reporting
Researchers at Children’s Hospital of Philadelphia (CHOP) have developed a custom-built application to automate determination of engraftment, a key outcome after hematopoietic stem cell transplant (HSCT). The application supersedes a tedious manual process and at the same time substantially improves accuracy of reported hematopoietic cell transplant engraftments.
MD Anderson Research Highlights: ESMO 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features upcoming oral presentations by MD Anderson researchers at the European Society for Medical Oncology (ESMO) Congress 2022 focused on clinical advances across a variety of cancer types. Highlights include promising early data from a novel T cell therapy for solid tumors, targeted therapy progress in rare and advanced cancers, biomarkers of immunotherapy response, and features associated with clinical outcomes in leptomeningeal disease. More information on ESMO content from MD Anderson can be found at MDAnderson.org/ESMO.
Novel study investigates cell therapy to treat swallowing disorders
Researchers have launched a groundbreaking study utilizing autologous muscle derived progenitor cells to increase tongue strength for patients struggling with difficulty swallowing, many of whom are cancer survivors.
MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant.
MD Anderson and Resilience launch joint venture to accelerate development and manufacturing of innovative cell therapies for cancer
MD Anderson and Resilience today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, which unites the strengths of both parties to accelerate the development and manufacturing of cell therapies for patients with cancer.
MD Anderson Research Highlights: ESMO 2021 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and clinical cancer research from MD Anderson experts. This special edition features oral presentations by MD Anderson researchers at the virtual European Society for Medical Oncology (ESMO) Congress 2021 on novel therapeutic approaches, including cell therapy for solid tumors, antibody drug conjugates targeting TROP2 and neoadjuvant pembrolizumab for advanced solid tumors with mismatch repair deficiencies.
MD Anderson and Bellicum Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe® (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch.
Engineered NK cells can eliminate glioblastoma stem cells
Preclinical research finds that glioblastoma stem cells can be targeted by NK cells, but they are able to evade immune attack by releasing TFG-β. Deleting the TFG-β receptor in NK cells renders them resistant to this and restores their anti-tumor activity.
Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants
A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. The study was published today in the Journal of Clinical Oncology.
Penn Medicine and Children’s Hospital of Philadelphia to Host Symposium on the Future of Cell and Gene Therapies
Penn Medicine and Children’s Hospital of Philadelphia (CHOP) will host a virtual event on May 6 and 7 that will bring together cell and gene therapy leaders from the two institutions and around the world to discuss the latest achievements in the field, novel strategies, and future developments and applications for chimeric antigen receptor, CAR, T cell therapy and more.
You are not a cat, but a cat could someday help treat your chronic kidney disease
The Wake Forest Institute for Regenerative Medicine is investigating how cats with chronic kidney disease could someday help inform treatment for humans.
Tip Sheet: Diversity in vaccine clinical trials, behind-the-scenes look at COVID-19 biostats, new cell therapy approved, plus meet ‘Megasphaera hutchinsoni’
SEATTLE — March 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.March is Women’s History month. We’d like to honor Dottie Thomas, known as the “mother of bone marrow transplantation.” She spent years working as a research partner alongside her husband, Nobel Prize-winning Dr.
Fred Hutch statement regarding the FDA approval of CD19 immunotherapy, lisocabtagene maraleucel
SEATTLE — Feb. 5, 2021 — Today the U.S. Food and Drug Administration approved the chimeric antigen receptor immunotherapy, Breyanzi (lisocabtagene maraleucel or liso-cel), for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies.The approval was granted to Bristol Myers Squibb, and development of the therapy was supported by physician-scientists at Fred Hutchinson Cancer Research Center.
Scientists Take Important Step Toward Using Retinal Cell Transplants to Treat Blindness
Retinal cells derived from a cadaver human eye survived when transplanted into the eyes of primate models, an important advance in the development of cell therapy to treat blindness, according to a study published on January 14 in Stem Cell Reports.
Potential Cellular Target for Eliminating Bone Breakdown in Osteoporosis Found
By disabling a function of a set of cells in mice, researchers appear to have halted the process that breaks down bone, a likely boon for osteoporosis treatment
Fine-tuning adoptive cell therapy for advanced cancers
In a new study looking at adoptive cell transfer products bearing a transgenic T-cell receptor (TCR), researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a discordant phenomenon in which a subset of patients displayed profoundly decreased expression of the transgenic TCR over time, despite the transgenic TCR being present at the DNA level.
CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.
Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program
Ziopharm and MD Anderson have announced a new research and development agreement to develop novel T-cell therapies using engineered T-cell receptors for solid tumors.
Cancer treatment: researcher makes breakthrough immunotherapy discovery
Dr. Christopher E. Rudd has discovered a new cell therapy approach that boosts the immune response of T lymphocytes to malignant tumours.